In A Win For Amgen, Court Blocks Sanofi/Regeneron's Praluent Sales In Germany

 
• By Mandy Jackson

A court in Dusseldorf ruled that Praluent infringes a patent for Amgen's better-selling PCSK9 inhibitor Repatha, saying that Sanofi and Regeneron must stop selling their biologic in Germany. It's unclear whether there will be any readthrough to ongoing patent disputes in other countries.

Gavel on chess board with figures. Law chess concept, 3D rendering
The PCSK9 patent chess game in Germany ended with a win for Amgen. • Source: Shutterstock

More from Legal & IP

More from Business